Basal Insulin in the Management of Patients With Diabetic Ketoacidosis

Status Completed

Clinical Trial Summary

The study is a multicenter, randomized controlled trial to compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in patients with diabetic ketoacidosis (DKA).

Clinical Trial Description

Diabetic ketoacidosis (DKA) is the most serious emergency in patients with diabetes. With an estimated 100,000 admissions per year in the United States, DKA is also the leading cause of death in children with type 1 diabetes, and accounts for a significant proportion of admissions in adult patients with type 1 and type 2 diabetes. The mainstay in the treatment of DKA involves the continuous intravenous (IV) infusion of regular insulin or the frequent subcutaneous (SC) injections of regular or rapid-acting insulin analogs. Multiple studies have reported successful protocols for insulin administration during the acute management of DKA, but they have failed to address the transition phase from IV to SC maintenance insulin regimen. The American Diabetes Association (ADA) position statement recommends the use of split-mixed insulin combination of regular and intermediate-acting insulin (NPH). This regimen, however, are associated with a high rate of hyperglycemia shortly after discontinuation of IV insulin and a risk of hypoglycemia during the hospital stay. Recently, the long-acting "basal" insulin glargine (Lantus®, Sanofi Aventis Pharmaceuticals) has been shown to facilitate glycemic control with lower rate of hypoglycemic events than intermediate-acting insulin in subjects with type 1 and type 2 diabetes. This study aims i) to determine the effects of giving a dose of glargine insulin shortly after starting an intravenous insulin infusion on glycemic control, time to resolve DKA, and rate of hypoglycemia in patients with DKA, and ii) to compare the safety and efficacy of basal/bolus (glargine/glulisine) insulin versus the standard split-mixed insulin regimen of NPH and regular insulin after the resolution of DKA. The hypothesis is that basal (lantus®) insulin as compared to NPH insulin shortly after the start of insulin infusion will improve inpatient glycemic control in patients with DKA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00590044
Study type	Interventional
Source	Emory University
Contact
Status	Completed
Phase	Phase 4
Start date	December 2007
Completion date	August 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Completed	`NCT03660189` - Two Bag System for Diabetic Ketoacidosis	N/A
Terminated	`NCT03066440` - Double Blinded Randomized Control Trial of Types of IVF in Children With DKA	Phase 4
Completed	`NCT04940897` - Use of Blood Ketone Meters to Improve Ambulance Hyperglycaemia Care	N/A
Completed	`NCT02930044` - Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis	N/A
Completed	`NCT04926740` - Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department	N/A
Terminated	`NCT04567225` - Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management	Phase 4
Completed	`NCT04017221` - Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
Recruiting	`NCT03717896` - Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis	Phase 2
Terminated	`NCT02548494` - Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes	N/A
Completed	`NCT02006342` - Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis	N/A
Completed	`NCT01753921` - Evaluation of a Non-invasive Brain Compliance Measurement Device
Completed	`NCT01365793` - Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis	Phase 3
Completed	`NCT00426413` - Ketosis Prone Diabetes in African-Americans	N/A
Not yet recruiting	`NCT05867797` - Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Terminated	`NCT04234867` - Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)	Phase 1
Not yet recruiting	`NCT05752279` - Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis	Phase 3
Completed	`NCT04825639` - Identifying Risk Factors for Developing AKI in Sepsis
Recruiting	`NCT05155917` - Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care	Phase 2
Recruiting	`NCT05383404` - Clinical and Laboratory Parameters Associated With Different Degrees of Dehydration Among Children With Diabetic Ketoacidosis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms